<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615287</url>
  </required_header>
  <id_info>
    <org_study_id>42/25-01-18</org_study_id>
    <nct_id>NCT03615287</nct_id>
  </id_info>
  <brief_title>Assessing Cardiovascular Dysfunction Pre- &amp; Post-treatment in Inflammatory Bowel Diseases</brief_title>
  <official_title>Assessment of Inflammation Load, Endothelial and Cardiac Function Before and After Medical and Surgical Treatment in Inflammatory Bowel Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare medical and surgery treatment in IBD patients and healthy
      controls, by assessing the endothelial and cardiac function and the inflammation status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare medical and surgery treatment in IBD patients and healthy
      controls, by assessing the endothelial and cardiac function and the inflammation status.

      In particular, three subject groups will be enrolled, as follows:

      40 patients [Crohn's disease (CD) &amp; ulcerative colitis (UC)] who will undergo medical
      treatment (Group A), 40 patients (CD &amp; UC) who will undergo surgery (Group B) and a healthy
      control group (Group C) comprising 40 subjects.

      Assessment of the inflammation load (CRP, WBC, IL-6, TNFa), the endothelial function (FMD,
      PWV, cIMT, endothelial glycocalyx) and the cardiac function - via echocardiographic
      parameters (systolic and diastolic echo values, tissue doppler imaging-GLS-strain rate) -
      will be carried out for every subject group in two phases: prior to treatment and four months
      after the treatment, as applicable.

      The objective is to investigate whether there is a statistically significant reduction of
      endothelial and cardiac dysfunction following medical and surgery treatment in IBD patients
      as well as to examine associations across the three groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of CFR</measure>
    <time_frame>Just before treatment and four (4) months after treatment</time_frame>
    <description>Change of coronary flow reserve values in echocardiography pre &amp; post treatment</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>40 subjects undergoing Medical Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>40 subjects undergoing Surgical Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>40 control subjects</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Assessment of the inflammation load through analysis of the values of CRP, WBC, IL-6, TNFa
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        IBD patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with IBD diagnosed &gt; 6 months via biopsy confirming the diagnosis

          -  Patients with IBD at an advanced &amp; non-controllable phase (IBD scores,clinical status,
             endoscopic and biochemical values) requiring the initiation of a new medical treatment
             or surgical intervention.

        Exclusion Criteria:

          -  Coronary Artery Disease

          -  Peripheral Arterial Disease

          -  Thromboembolic Disease (acute or chronic)

          -  Heart failure of any cause

          -  Valvular Disease

          -  Congenital Heart Defect

          -  Heart Rhythm Disorder

          -  Stroke, Renal or liver failure, malignancy, endocrine disorder

          -  Other autoimmune disorder or angiitis

          -  IBD diagnosed &lt; 6 months

          -  BMI &gt; 40 Kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioannis Papaconstantinou, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>2nd Department of Surgery Aretaieion Hospital-University of Athens-Greece</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignatios Ikonomidis, PhD</last_name>
    <phone>+306944805732</phone>
    <email>ignoik@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charilaos Triantafyllou, MD</last_name>
    <phone>+306942202084</phone>
    <email>chtriantaf@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>''Attikon'' University General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignatios Ikonomidis, MD</last_name>
      <phone>00302105831264</phone>
      <email>ignoik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignatios Ikonomidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Ignatios Ikonomidis</investigator_full_name>
    <investigator_title>Associate Professor of Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

